Sugi Predict

Sugi Predict / Compounds / SCHEMBL21521679

SCHEMBL21521679

SCHEMBL21521679

CC(C)(C)OC(=O)N1CC(Nc2ccc(C#N)cn2)C1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 3/20 0.49
▸ IRAK4 Q9NWZ3 2/20 0.48
▸ CCR6 P51684 4/20 0.48
▸ CYP3A4 P08684 2/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ HSD11B1 P28845 2/20 0.48
▸ HSD11B2 P80365 1/20 0.48
▸ CCNK O75909 2/20 0.47
▸ CDK12 Q9NYV4 2/20 0.47
▸ EGLN2 Q96KS0 2/20 0.46
▸ DPP4 P27487 3/20 0.45
▸ DPP8 Q6V1X1 1/20 0.45
▸ DPP9 Q86TI2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31465059 1.00 GPR119 (0.49) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL1036415 0.91 CYP3A4 (0.58) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL23292365 0.91 CYP3A4 (0.58) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL1036416 0.91 CYP3A4 (0.58) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL1120230 0.89 CYP3A4 (0.52) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL1938685 0.89 GPR119 (0.60) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL26126144 0.85 IRAK4 (0.48) GPR119IRAK4EGLN2
SCHEMBL21824798 0.83 ALDH1A1 (0.53) GPR119IRAK4EGLN2
SCHEMBL2708722 0.82 DPP4 (0.44) GPR119IRAK4CCR6CYP3A4CYP2D6
SCHEMBL21853973 0.81 CCNK (0.53) CCR6CYP3A4CYP2D6CYP2C9HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 — — US disclosed
EP-4594314-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS Azkarra Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
WO-2024073133-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 — — EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 — — US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 — — EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 — — US disclosed
US-11014913-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2021-05-25 — — US disclosed
EP-3788040-A1 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2021-03-10 — — EP disclosed
CN-112424188-A Pyridazinones as PARP7 inhibitors 里邦医疗公司 2021-02-26 — — CN disclosed
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2021-01-28 — — US disclosed
US-10870641-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2020-12-22 — — US disclosed
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2020-04-23 — — US disclosed
US-10550105-B2 Pyridazinones as PARP7 inhibitors Ribon Therapeutics Inc. (US) 2020-02-04 — — US disclosed
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2019-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210024502-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-10550105-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-20190330194-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 GPR119 3786/4885IRAK4 1372/4885CCR6 477/4885
US-11014913-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-10870641-B2 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885
US-20200123134-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 GPR119 4379/4885IRAK4 2039/4885CCR6 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.